眼科指南

订阅

MedSci主页 / 所有栏目 / 眼科指南

2022 专家共识：替妥木单抗治疗甲状腺眼病

2022-03-24 国外眼科专家协作组（统称） J Neuroophthalmol

甲状腺眼病替妥木单抗

替妥木单抗（Teprotumumab）可通过抑制胰岛素样生长因子1受体（IGF-1R）逆转甲状腺眼病（TED）的疾病进程，于2020年获得FDA批准上市。本文主要针对TED使用替妥木单抗治疗提供临床建

中文标题：

2022 专家共识：替妥木单抗治疗甲状腺眼病

英文标题：

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach

发布机构：

国外眼科专家协作组（统称）

发布日期：

2022-03-24

简要介绍：

替妥木单抗（Teprotumumab）可通过抑制胰岛素样生长因子1受体（IGF-1R）逆转甲状腺眼病（TED）的疾病进程，于2020年获得FDA批准上市。本文主要针对TED使用替妥木单抗治疗提供临床建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 专家共识：替妥木单抗治疗甲状腺眼病.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a52c61c002a156f9, title=2022 专家共识：替妥木单抗治疗甲状腺眼病, enTitle=Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach, guiderFrom=J Neuroophthalmol, authorId=0, author=, summary=替妥木单抗（Teprotumumab）可通过抑制胰岛素样生长因子1受体（IGF-1R）逆转甲状腺眼病（TED）的疾病进程，于2020年获得FDA批准上市。本文主要针对TED使用替妥木单抗治疗提供临床建, cover=https://img.medsci.cn/20220418/1650287503274_1608702.jpg, journalId=0, articlesId=null, associationId=959, associationName=国外眼科专家协作组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Mar 24 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">替妥木单抗（Teprotumumab）可通过抑制胰岛素样生长因子1受体（IGF-1R）逆转甲状腺眼病（TED）的疾病进程，于2020年获得FDA批准上市。本文主要针对TED使用替妥木单抗治疗提供临床建议。</span></p>, tagList=[TagDto(tagId=76319, tagName=甲状腺眼病), TagDto(tagId=436896, tagName=替妥木单抗)], categoryList=[CategoryDto(categoryId=32, categoryName=眼科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=17142, appHits=88, showAppHits=0, pcHits=1180, showPcHits=17054, likes=0, shares=19, comments=2, approvalStatus=1, publishedTime=Tue Apr 19 15:09:00 CST 2022, publishedTimeString=2022-03-24, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Apr 18 21:13:36 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 22:05:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 专家共识：替妥木单抗治疗甲状腺眼病.pdf)])
2022 专家共识：替妥木单抗治疗甲状腺眼病.pdf
下载请点击：
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1231878, encodeId=8d8212318e8b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5b68221406, createdName=ms3000001860629395, createdTime=Mon Jul 11 21:19:50 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213260, encodeId=967c1213260ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Thu Apr 21 20:19:42 CST 2022, time=2022-04-21, status=1, ipAttribution=)]
    2022-07-11 ms3000001860629395

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1231878, encodeId=8d8212318e8b6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5b68221406, createdName=ms3000001860629395, createdTime=Mon Jul 11 21:19:50 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213260, encodeId=967c1213260ca, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6c75291303, createdName=14863d7cm33暂无昵称, createdTime=Thu Apr 21 20:19:42 CST 2022, time=2022-04-21, status=1, ipAttribution=)]
    2022-04-21 14863d7cm33暂无昵称

    学习了

    0